ArticleJournal of diabetes2024

The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agonist on patients with type 2 diabetes: A population-based study.

Zhiyuan Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.